BioSpace News Archive

BIOLASE, Inc. announced plans to launch a second season of the popular podcast series, “BIOLASE: Advancing Dentistry.” Due to the overwhelmingly positive response from the dental community, the rising interest and popular demand, the second season will maintain the high level of excellence associated with the BIOLASE podcast.

Reata Pharmaceuticals, Inc. announced that management will participate in the Barclays Global Healthcare Conference held next week, March 14-16, in Miami, Florida.

Merck announced today that the U.S. Food and Drug Administration (FDA) has approved the addition of the intramuscular (IM) route of administration to the United States Product Insert (USPI) for Merck’s MMRV family of vaccines: M-M-R®II, VARIVAX®, and ProQuad®.

Voyager Therapeutics, Inc. today announced that Novartis AG (NYSE: NVS) has exercised its options to license novel capsids generated from Voyager’s TRACER™ capsid discovery platform for use in gene therapy programs against two undisclosed neurologic disease targets.

Tango Therapeutics, Inc. today announced that, effective March 1, 2023, the Compensation Committee of Tango Therapeutics’ Board of Directors granted non-qualified stock options to purchase an aggregate of 637,000 shares of its common stock and an aggregate of 106,250 restricted stock units (RSUs) to two new employees.

Invivyd, Inc., a clinical stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announces the election of VYD222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19.

Krystal Biotech, Inc. today announced the appointment of Catherine Mazzacco to its Board of Directors.

Avanos Medical, Inc. (NYSE: AVNS) today announced that Dr. Lisa Egbuonu-Davis , currently vice president, medical innovations, for DH Diagnostics, LLC, an affiliate of Danaher Corporation, has been appointed as a new independent member of the Avanos board of directors and will serve as a member of the compliance and governance committees.

Milestone Pharmaceuticals Inc. today announced significant progress in clinical and regulatory activities for etripamil, the Company’s investigational calcium channel blocker that is administered by patients outside of the healthcare setting to treat paroxysmal supraventricular tachycardia (PSVT).

HanAll Biopharma Co., Ltd. (KRX: 009420. KS) announced that its licensed partner Harbour BioMed in Greater China reported positive top-line results from its pivotal Phase 3 clinical trial of batoclimab in generalized myasthenia gravis (gMG) patients.